1535-45-1

Usage

Uses

Used in Pharmaceutical Industry:
3-(aminosulfonyl)-4-fluorobenzoic acid is used as a building block for the synthesis of various pharmaceuticals. Its unique molecular structure, including the fluorine atom and the aminosulfonyl group, contributes to its potential biological activity and makes it a valuable component in the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical sector, 3-(aminosulfonyl)-4-fluorobenzoic acid is also utilized as a key component in the synthesis of different agrochemicals. Its presence in these compounds can enhance their effectiveness and selectivity, leading to improved outcomes in agricultural applications.
Used in Medicinal Chemistry Research:
3-(aminosulfonyl)-4-fluorobenzoic acid is employed as a subject of study in medicinal chemistry. Its biological activity and the unique properties conferred by the fluorine and aminosulfonyl groups make it an interesting compound for exploring new therapeutic agents and understanding their mechanisms of action.

Upstream product

• 456-22-4 4-Fluorobenzoic acid 
• 438539-71-0 2-fluoro-5-methylbenzenesulphonamide 
• 2267-40-5 3-chlorosulfonyl-4-fluoro-benzoic acid 

Downstream Products

• 1204574-89-9 methyl 4-cyclopropylamino-3-sulphamoylbenzoate 
• 1110781-81-1 4-fluoro-N-(3-methoxy-phenyl)-3-sulfamoyl-benzamide 
• 656-93-9 4-fluoro-3-sulphamoylbenzamide 

Relevant academic research and scientific papers

Synthesis of a new series of 3-functionalised-1-phenyl-1,2,3-triazole sulfamoylbenzamides as carbonic anhydrase I, II, IV and IX inhibitors

The synthesis of a novel series of 3-functionalised benzenesulfonamides incorporating phenyl-1,2,3-triazole with an amide linker was achieved by using the “click-tail” approach. The new compounds, including the intermediates, were assayed as inhibitors of human carbonic anhydrase (CA, EC 4.2.1.1) isoforms hCA I and II (cytosolic isoforms) and also for hCA IV and IX (transmembrane isoforms) taking acetazolamide as standard drug. Most of these compounds exhibited excellent activity against all these isoforms. hCA I was inhibited with Kis in the range of 50.8–966.8 nM, while the glaucoma associated hCA II was inhibited with Kis in the range of 6.5–760.0 nM. Isoform hCA IV was inhibited with Kis in the range of 65.3–957.5 nM, whereas the tumor associated hypoxia induced hCA IX was inhibited with Kis in the range of 30.8–815.9 nM. The structure activity relationship study for the 3-functionalised-1-phenyl-1,2,3-triazole sulfamoylbenzamides against these isoforms was also inferred from the results.

2-Halobenzenesulfonyl chlorides in the synthesis of pyrido[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide derivatives

A number of new functional derivatives of pyrido[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide was obtained based on the reactions of 2-halobenzenesulfonyl chlorides with 2-aminopyridine derivatives. A quantitative criterion for the evaluation of a possibility for the reaction to proceed under noncatalytic conditions depending on the type of halogen and substituents in the starting compounds was suggested.

Design, synthesis, and pharmacological evaluation of highly potent and selective dipeptidyl peptidase-4 inhibitors

The optimization of a series of fused β-homophenylalanine inhibitors of dipeptidyl peptidase-4 (DPP-4) is described. Modification on the P2-binding moiety of 6 (IC50 = 10 nM) led to the discovery of β-homophenylalanine derivatives containing pyrrolidin-2-ylmethyl amides. The introduction of a sulfamine in the meta position of the phenyl ring improved the potency against DPP-4 (6-12-fold increase). Compound 14k showed DPP-4 inhibitory activity with an IC50 value of 0.87 nM. Meanwhile, in vivo experiments exhibited that 14h had an efficiency comparable to sitagliptin at the dose of 10 mg/kg.

Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compostions containing them

Compounds of formula (I): wherein: RCy represents an unsubstituted or substituted cycloalkyl group or cycloalkylalkyl group,R1, R2, R3 and R4, which may be the same or different, each represent a hydrogen or halogen atom or a nitro group; a cyano group; a hydroxy group; an alkoxy group; an alkyl group; an unsubstituted or substituted amino group; a carboxy group; an alkoxycarbonyl group; an aryloxycarbonyl group; an unsubstituted or substituted aminocarbonyl group. Medicinal products containing the same which are useful in treating or preventing conditions treatable by an AMPA receptor modulator.

CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS

The present invention relates to compounds of formula (I) or pharmaceutically acceptable derivatives thereof, useful in the treatment or prophylaxis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).